調査レポート | • レポートコード：GIR-2104Z10224 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、108ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療・医薬品 |
| Single User | ￥494,160 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥741,240 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥988,320 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、腫瘍学バイオシミラーのグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。腫瘍学バイオシミラーの種類別市場規模（モノクローナル抗体、造血剤、G-CSF、その他）、用途別市場規模（小売薬局、病院薬局、オンライン薬局）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・腫瘍学バイオシミラーの市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Celltrion、Biocon、Dr. Reddy’s Laboratories、STADA Arzneimittel AG、Intas Pharmaceuticals、Pfizer、Sandoz International、Teva Pharmaceutical Industries Ltd、Apotex、BIOCAD ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：モノクローナル抗体、造血剤、G-CSF、その他 ・用途別分析2016年-2026年：小売薬局、病院薬局、オンライン薬局 ・腫瘍学バイオシミラーの北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・腫瘍学バイオシミラーのヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・腫瘍学バイオシミラーのアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・腫瘍学バイオシミラーの南米市場規模2016年-2026年：ブラジル、アルゼンチン ・腫瘍学バイオシミラーの中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Oncology Biosimilars market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Oncology Biosimilars size is estimated to be xx million in 2020 from USD xx million in 2019, with a change of XX% between 2019 and 2020. The global Oncology Biosimilars market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Oncology Biosimilars market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Monoclonal Antibody
Hematopoietic Agents
G-CSF
Others
Market segment by Application can be divided into
Retail Pharmacies
Hospital Pharmacy
Online Pharmacy
The key market players for global Oncology Biosimilars market are listed below:
Celltrion
Biocon
Dr. Reddy’s Laboratories
STADA Arzneimittel AG
Intas Pharmaceuticals
Pfizer
Sandoz International
Teva Pharmaceutical Industries Ltd
Apotex
BIOCAD
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
1 Market Overview
1.1 Oncology Biosimilars Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Oncology Biosimilars Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Monoclonal Antibody
1.2.3 Hematopoietic Agents
1.2.4 G-CSF
1.2.5 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Oncology Biosimilars Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Retail Pharmacies
1.3.3 Hospital Pharmacy
1.3.4 Online Pharmacy
1.4 Global Oncology Biosimilars Market Size & Forecast
1.4.1 Global Oncology Biosimilars Sales in Value (2016-2026))
1.4.2 Global Oncology Biosimilars Sales in Volume (2016-2026)
1.4.3 Global Oncology Biosimilars Price by Type (2016-2026) & (US$/Unit)
1.5 Global Oncology Biosimilars Production Capacity Analysis
1.5.1 Global Oncology Biosimilars Total Production Capacity (2016-2026)
1.5.2 Global Oncology Biosimilars Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Oncology Biosimilars Market Drivers
1.6.2 Oncology Biosimilars Market Restraints
1.6.3 Oncology Biosimilars Trends Analysis
2 Manufacturers Profiles
2.1 Celltrion
2.1.1 Celltrion Details
2.1.2 Celltrion Major Business
2.1.3 Celltrion Oncology Biosimilars Product and Services
2.1.4 Celltrion Oncology Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.2 Biocon
2.2.1 Biocon Details
2.2.2 Biocon Major Business
2.2.3 Biocon Oncology Biosimilars Product and Services
2.2.4 Biocon Oncology Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.3 Dr. Reddy’s Laboratories
2.3.1 Dr. Reddy’s Laboratories Details
2.3.2 Dr. Reddy’s Laboratories Major Business
2.3.3 Dr. Reddy’s Laboratories Oncology Biosimilars Product and Services
2.3.4 Dr. Reddy’s Laboratories Oncology Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.4 STADA Arzneimittel AG
2.4.1 STADA Arzneimittel AG Details
2.4.2 STADA Arzneimittel AG Major Business
2.4.3 STADA Arzneimittel AG Oncology Biosimilars Product and Services
2.4.4 STADA Arzneimittel AG Oncology Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.5 Intas Pharmaceuticals
2.5.1 Intas Pharmaceuticals Details
2.5.2 Intas Pharmaceuticals Major Business
2.5.3 Intas Pharmaceuticals Oncology Biosimilars Product and Services
2.5.4 Intas Pharmaceuticals Oncology Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.6 Pfizer
2.6.1 Pfizer Details
2.6.2 Pfizer Major Business
2.6.3 Pfizer Oncology Biosimilars Product and Services
2.6.4 Pfizer Oncology Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.7 Sandoz International
2.7.1 Sandoz International Details
2.7.2 Sandoz International Major Business
2.7.3 Sandoz International Oncology Biosimilars Product and Services
2.7.4 Sandoz International Oncology Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.8 Teva Pharmaceutical Industries Ltd
2.8.1 Teva Pharmaceutical Industries Ltd Details
2.8.2 Teva Pharmaceutical Industries Ltd Major Business
2.8.3 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Product and Services
2.8.4 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.9 Apotex
2.9.1 Apotex Details
2.9.2 Apotex Major Business
2.9.3 Apotex Oncology Biosimilars Product and Services
2.9.4 Apotex Oncology Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.10 BIOCAD
2.10.1 BIOCAD Details
2.10.2 BIOCAD Major Business
2.10.3 BIOCAD Oncology Biosimilars Product and Services
2.10.4 BIOCAD Oncology Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
3 Oncology Biosimilars Sales by Manufacturer
3.1 Global Oncology Biosimilars Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Oncology Biosimilars Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Oncology Biosimilars
3.4 Market Concentration Rate
3.4.1 Top 3 Oncology Biosimilars Manufacturer Market Share
3.4.2 Top 6 Oncology Biosimilars Manufacturer Market Share
3.5 Global Oncology Biosimilars Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Oncology Biosimilars Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Oncology Biosimilars Market Size by Region
4.1.1 Global Oncology Biosimilars Sales in Volume by Region (2016-2026)
4.1.2 Global Oncology Biosimilars Revenue by Region (2016-2026)
4.2 North America Oncology Biosimilars Revenue (2016-2026)
4.3 Europe Oncology Biosimilars Revenue (2016-2026)
4.4 Asia-Pacific Oncology Biosimilars Revenue (2016-2026)
4.5 South America Oncology Biosimilars Revenue (2016-2026)
4.6 Middle East and Africa Oncology Biosimilars Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Oncology Biosimilars Sales in Volume by Type (2016-2026)
5.2 Global Oncology Biosimilars Revenue by Type (2016-2026)
5.3 Global Oncology Biosimilars Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Oncology Biosimilars Sales in Volume by Application (2016-2026)
6.2 Global Oncology Biosimilars Revenue by Application (2016-2026)
6.3 Global Oncology Biosimilars Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Oncology Biosimilars Sales by Type (2016-2026)
7.2 North America Oncology Biosimilars Sales by Application (2016-2026)
7.3 North America Oncology Biosimilars Market Size by Country
7.3.1 North America Oncology Biosimilars Sales in Volume by Country (2016-2026)
7.3.2 North America Oncology Biosimilars Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Oncology Biosimilars Sales by Type (2016-2026)
8.2 Europe Oncology Biosimilars Sales by Application (2016-2026)
8.3 Europe Oncology Biosimilars Market Size by Country
8.3.1 Europe Oncology Biosimilars Sales in Volume by Country (2016-2026)
8.3.2 Europe Oncology Biosimilars Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Oncology Biosimilars Sales by Type (2016-2026)
9.2 Asia-Pacific Oncology Biosimilars Sales by Application (2016-2026)
9.3 Asia-Pacific Oncology Biosimilars Market Size by Region
9.3.1 Asia-Pacific Oncology Biosimilars Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Oncology Biosimilars Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Oncology Biosimilars Sales by Type (2016-2026)
10.2 South America Oncology Biosimilars Sales by Application (2016-2026)
10.3 South America Oncology Biosimilars Market Size by Country
10.3.1 South America Oncology Biosimilars Sales in Volume by Country (2016-2026)
10.3.2 South America Oncology Biosimilars Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Oncology Biosimilars Sales by Type (2016-2026)
11.2 Middle East & Africa Oncology Biosimilars Sales by Application (2016-2026)
11.3 Middle East & Africa Oncology Biosimilars Market Size by Country
11.3.1 Middle East & Africa Oncology Biosimilars Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Oncology Biosimilars Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Oncology Biosimilars Typical Distributors
12.3 Oncology Biosimilars Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Oncology Biosimilars Revenue by Type, (USD Million), 2021-2026
Table 2. Global Oncology Biosimilars Revenue by Application, (USD Million), 2021-2026
Table 3. Celltrion Basic Information, Manufacturing Base and Competitors
Table 4. Celltrion Major Business
Table 5. Celltrion Oncology Biosimilars Product and Services
Table 6. Celltrion Oncology Biosimilars Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Biocon Basic Information, Manufacturing Base and Competitors
Table 8. Biocon Major Business
Table 9. Biocon Oncology Biosimilars Product and Services
Table 10. Biocon Oncology Biosimilars Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Dr. Reddy’s Laboratories Basic Information, Manufacturing Base and Competitors
Table 12. Dr. Reddy’s Laboratories Major Business
Table 13. Dr. Reddy’s Laboratories Oncology Biosimilars Product and Services
Table 14. Dr. Reddy’s Laboratories Oncology Biosimilars Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. STADA Arzneimittel AG Basic Information, Manufacturing Base and Competitors
Table 16. STADA Arzneimittel AG Major Business
Table 17. STADA Arzneimittel AG Oncology Biosimilars Product and Services
Table 18. STADA Arzneimittel AG Oncology Biosimilars Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Intas Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 20. Intas Pharmaceuticals Major Business
Table 21. Intas Pharmaceuticals Oncology Biosimilars Product and Services
Table 22. Intas Pharmaceuticals Oncology Biosimilars Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Pfizer Basic Information, Manufacturing Base and Competitors
Table 24. Pfizer Major Business
Table 25. Pfizer Oncology Biosimilars Product and Services
Table 26. Pfizer Oncology Biosimilars Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Sandoz International Basic Information, Manufacturing Base and Competitors
Table 28. Sandoz International Major Business
Table 29. Sandoz International Oncology Biosimilars Product and Services
Table 30. Sandoz International Oncology Biosimilars Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Teva Pharmaceutical Industries Ltd Basic Information, Manufacturing Base and Competitors
Table 32. Teva Pharmaceutical Industries Ltd Major Business
Table 33. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Product and Services
Table 34. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Apotex Basic Information, Manufacturing Base and Competitors
Table 36. Apotex Major Business
Table 37. Apotex Oncology Biosimilars Product and Services
Table 38. Apotex Oncology Biosimilars Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 39. BIOCAD Basic Information, Manufacturing Base and Competitors
Table 40. BIOCAD Major Business
Table 41. BIOCAD Oncology Biosimilars Product and Services
Table 42. BIOCAD Oncology Biosimilars Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 43. Global Oncology Biosimilars Sales by Manufacturer (2019-2021e) & (K Units)
Table 44. Global Oncology Biosimilars Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 45. Market Position of Manufacturers in Oncology Biosimilars, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 46. Global Oncology Biosimilars Production Capacity by Company, (K Units): 2020 VS 2021
Table 47. Head Office and Oncology Biosimilars Production Site of Key Manufacturer
Table 48. Global Oncology Biosimilars Sales by Region (2016-2021e) & (K Units)
Table 49. Global Oncology Biosimilars Sales by Region (2021-2026) & (K Units)
Table 50. Global Oncology Biosimilars Revenue by Region (2016-2021e) & (USD Million)
Table 51. Global Oncology Biosimilars Revenue by Region (2021-2026) & (USD Million)
Table 52. Global Oncology Biosimilars Sales by Type (2016-2021e) & (K Units)
Table 53. Global Oncology Biosimilars Sales by Type (2021-2026) & (K Units)
Table 54. Global Oncology Biosimilars Revenue by Type (2016-2021e) & (USD Million)
Table 55. Global Oncology Biosimilars Revenue by Type (2021-2026) & (USD Million)
Table 56. Global Oncology Biosimilars Price by Type (2016-2021e) & (US$/Unit)
Table 57. Global Oncology Biosimilars Price by Type (2021-2026) & (US$/Unit)
Table 58. Global Oncology Biosimilars Sales by Application (2016-2021e) & (K Units)
Table 59. Global Oncology Biosimilars Sales by Application (2021-2026) & (K Units)
Table 60. Global Oncology Biosimilars Revenue by Application (2016-2021e) & (USD Million)
Table 61. Global Oncology Biosimilars Revenue by Application (2021-2026) & (USD Million)
Table 62. Global Oncology Biosimilars Price by Application (2016-2021e) & (US$/Unit)
Table 63. Global Oncology Biosimilars Price by Application (2021-2026) & (US$/Unit)
Table 64. North America Oncology Biosimilars Sales by Country (2016-2021e) & (K Units)
Table 65. North America Oncology Biosimilars Sales by Country (2021-2026) & (K Units)
Table 66. North America Oncology Biosimilars Revenue by Country (2016-2021e) & (USD Million)
Table 67. North America Oncology Biosimilars Revenue by Country (2021-2026) & (USD Million)
Table 68. North America Oncology Biosimilars Sales by Type (2016-2021e) & (K Units)
Table 69. North America Oncology Biosimilars Sales by Type (2021-2026) & (K Units)
Table 70. North America Oncology Biosimilars Sales by Application (2016-2021e) & (K Units)
Table 71. North America Oncology Biosimilars Sales by Application (2021-2026) & (K Units)
Table 72. Europe Oncology Biosimilars Sales by Country (2016-2021e) & (K Units)
Table 73. Europe Oncology Biosimilars Sales by Country (2021-2026) & (K Units)
Table 74. Europe Oncology Biosimilars Revenue by Country (2016-2021e) & (USD Million)
Table 75. Europe Oncology Biosimilars Revenue by Country (2021-2026) & (USD Million)
Table 76. Europe Oncology Biosimilars Sales by Type (2016-2021e) & (K Units)
Table 77. Europe Oncology Biosimilars Sales by Type (2021-2026) & (K Units)
Table 78. Europe Oncology Biosimilars Sales by Application (2016-2021e) & (K Units)
Table 79. Europe Oncology Biosimilars Sales by Application (2021-2026) & (K Units)
Table 80. Asia-Pacific Oncology Biosimilars Sales by Region (2016-2021e) & (K Units)
Table 81. Asia-Pacific Oncology Biosimilars Sales by Region (2021-2026) & (K Units)
Table 82. Asia-Pacific Oncology Biosimilars Revenue by Region (2016-2021e) & (USD Million)
Table 83. Asia-Pacific Oncology Biosimilars Revenue by Region (2021-2026) & (USD Million)
Table 84. Asia-Pacific Oncology Biosimilars Sales by Type (2016-2021e) & (K Units)
Table 85. Asia-Pacific Oncology Biosimilars Sales by Type (2021-2026) & (K Units)
Table 86. Asia-Pacific Oncology Biosimilars Sales by Application (2016-2021e) & (K Units)
Table 87. Asia-Pacific Oncology Biosimilars Sales by Application (2021-2026) & (K Units)
Table 88. South America Oncology Biosimilars Sales by Country (2016-2021e) & (K Units)
Table 89. South America Oncology Biosimilars Sales by Country (2021-2026) & (K Units)
Table 90. South America Oncology Biosimilars Revenue by Country (2016-2021e) & (USD Million)
Table 91. South America Oncology Biosimilars Revenue by Country (2021-2026) & (USD Million)
Table 92. South America Oncology Biosimilars Sales by Type (2016-2021e) & (K Units)
Table 93. South America Oncology Biosimilars Sales by Type (2021-2026) & (K Units)
Table 94. South America Oncology Biosimilars Sales by Application (2016-2021e) & (K Units)
Table 95. South America Oncology Biosimilars Sales by Application (2021-2026) & (K Units)
Table 96. Middle East & Africa Oncology Biosimilars Sales by Country (2016-2021e) & (K Units)
Table 97. Middle East & Africa Oncology Biosimilars Sales by Country (2021-2026) & (K Units)
Table 98. Middle East & Africa Oncology Biosimilars Revenue by Country (2016-2021e) & (USD Million)
Table 99. Middle East & Africa Oncology Biosimilars Revenue by Country (2021-2026) & (USD Million)
Table 100. Middle East & Africa Oncology Biosimilars Sales by Type (2016-2021e) & (K Units)
Table 101. Middle East & Africa Oncology Biosimilars Sales by Type (2021-2026) & (K Units)
Table 102. Middle East & Africa Oncology Biosimilars Sales by Application (2016-2021e) & (K Units)
Table 103. Middle East & Africa Oncology Biosimilars Sales by Application (2021-2026) & (K Units)
Table 104. Direct Channel Pros & Cons
Table 105. Indirect Channel Pros & Cons
Table 106. Oncology Biosimilars Typical Distributors
Table 107. Oncology Biosimilars Typical Customers
List of Figures
Figure 1. Oncology Biosimilars Picture
Figure 2. Global Oncology Biosimilars Sales Market Share by Type in 2020
Figure 3. Monoclonal Antibody
Figure 4. Hematopoietic Agents
Figure 5. G-CSF
Figure 6. Others
Figure 7. Global Oncology Biosimilars Sales Market Share by Application in 2020
Figure 8. Retail Pharmacies
Figure 9. Hospital Pharmacy
Figure 10. Online Pharmacy
Figure 11. Global Oncology Biosimilars Market Size, (USD Million) & (K Units): 2020 VS 2021 VS 2026
Figure 12. Global Oncology Biosimilars Market Size and Forecast (2016-2026) & (USD Million)
Figure 13. United States Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 14. Canada Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 15. Mexico Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 16. Germany Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 17. France Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 18. United Kingdom Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 19. Russia Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 20. Italy Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 21. China Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 22. Japan Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 23. Korea Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 24. India Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 25. Southeast Asia Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 26. Australia Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 27. Brazil Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 28. Egypt Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 29. Saudi Arabia Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 30. South Africa Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 31. Turkey Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 32. Global Oncology Biosimilars Sales (2016-2026) & (K Units)
Figure 33. Global Oncology Biosimilars Production Capacity (2016-2026) & (K Units)
Figure 34. Global Oncology Biosimilars Production Capacity by Geographic Region: 2020 VS 2021
Figure 35. Oncology Biosimilars Market Drivers
Figure 36. Oncology Biosimilars Market Restraints
Figure 37. Oncology Biosimilars Market Trends
Figure 38. Global Oncology Biosimilars Sales Market Share by Manufacturer in 2020
Figure 39. Global Oncology Biosimilars Revenue Market Share by Manufacturer in 2020
Figure 40. Oncology Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 41. Top 3 Oncology Biosimilars Manufacturer (Revenue) Market Share in 2020
Figure 42. Top 6 Oncology Biosimilars Manufacturer (Revenue) Market Share in 2020
Figure 43. Global Oncology Biosimilars Sales Market Share by Region (2016-2026)
Figure 44. Global Oncology Biosimilars Revenue Market Share by Region (2016-2026)
Figure 45. North America Oncology Biosimilars Revenue (2016-2026) & (USD Million)
Figure 46. Europe Oncology Biosimilars Revenue (2016-2026) & (USD Million)
Figure 47. Asia-Pacific Oncology Biosimilars Revenue (2016-2026) & (USD Million)
Figure 48. South America Oncology Biosimilars Revenue (2016-2026) & (USD Million)
Figure 49. Middle East & Africa Oncology Biosimilars Revenue (2016-2026) & (USD Million)
Figure 50. Global Oncology Biosimilars Sales Market Share by Type (2016-2026)
Figure 51. Global Oncology Biosimilars Revenue Market Share by Type (2016-2026)
Figure 52. Global Oncology Biosimilars Price by Type (2016-2026) & (US$/Unit)
Figure 53. Global Oncology Biosimilars Sales Market Share by Application (2016-2026)
Figure 54. Global Oncology Biosimilars Revenue Market Share by Application (2016-2026)
Figure 55. Global Oncology Biosimilars Price by Application (2016-2026) & (US$/Unit)
Figure 56. North America Oncology Biosimilars Sales Market Share by Country (2016-2026)
Figure 57. North America Oncology Biosimilars Revenue Market Share by Country (2016-2026)
Figure 58. North America Oncology Biosimilars Sales Market Share by Type (2016-2026)
Figure 59. North America Oncology Biosimilars Sales Market Share by Application (2016-2026)
Figure 60. Europe Oncology Biosimilars Sales Market Share by Country (2016-2026)
Figure 61. Europe Oncology Biosimilars Revenue Market Share by Country (2016-2026)
Figure 62. Europe Oncology Biosimilars Sales Market Share by Type (2016-2026)
Figure 63. Europe Oncology Biosimilars Sales Market Share by Application (2016-2026)
Figure 64. Asia-Pacific Oncology Biosimilars Sales Market Share by Region (2016-2026)
Figure 65. Asia-Pacific Oncology Biosimilars Revenue Market Share by Region (2016-2026)
Figure 66. Asia-Pacific Oncology Biosimilars Sales Market Share by Region (2016-2026)
Figure 67. Asia-Pacific Oncology Biosimilars Sales Market Share by Application (2016-2026)
Figure 68. South America Oncology Biosimilars Sales Market Share by Country (2016-2026)
Figure 69. South America Oncology Biosimilars Revenue Market Share by Country (2016-2026)
Figure 70. South America Oncology Biosimilars Sales Market Share by Type (2016-2026)
Figure 71. South America Oncology Biosimilars Sales Market Share by Application (2016-2026)
Figure 72. Middle East & Africa Oncology Biosimilars Sales Market Share by Country (2016-2026)
Figure 73. Middle East & Africa Oncology Biosimilars Revenue Market Share by Country (2016-2026)
Figure 74. Middle East & Africa Oncology Biosimilars Sales Market Share by Type (2016-2026)
Figure 75. Middle East & Africa Oncology Biosimilars Sales Market Share by Application (2016-2026)
Figure 76. Sales Channel: Direct Channel vs Indirect Channel
Figure 77. Methodology
Figure 78. Research Process and Data Source
世界のグリコシル化バイオシミラー市場規模・現状・予測（2021年-2027年） Glycosylated Biosimilars include mA, EPO etc in this report. Market Analysis and Insights: Global Glycosylated Biosimilars Market The global Glycosylated Biosimilars market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industr…- 世界のペプチドバイオシミラー市場規模・現状・予測（2021年-2027年） Peptides are short chains of amino acid monomers linked by peptide (amide) bonds. The statistic scope in this report is peptides biosimilars. Market Analysis and Insights: Global Peptides Biosimilars Market The global Peptides Biosimilars market size is projected to reach US$ XX million by 2026, fro…
- 世界のバイオシミラー/フォローオンバイオロジクス市場規模・現状・予測（2021年-2027年） Biosimilars or follow-on-biologics are the “copied” and licensed versions of those reference biologics that have undergone patent expiration. Biosimilars development and validation with reference biologics is a crucial aspect of the overall development process. Market Analysis and Insights: Global …
- 世界の組換え非グリコシル化タンパク質バイオシミラー市場規模・現状・予測（2021年-2027年） Recombinant non-glycosylated proteins include human growth hormone, granulocyte colony-stimulating factor, interferons, and insulin. The statistic scope in this report is Recombinant non-glycosylated proteins biosimilars. Market Analysis and Insights: Global Recombinant Non-Glycosylated Proteins Bio…
- 世界の網膜バイオシミラー市場 2021：企業別、地域別、種類・用途別 The Retinal Biosimilars market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations…